Colin Kellaher. By
Merck & Co. and Isai Co. said on Monday that the European Commission has approved the combination of Christian’s Lenvima and Merck’s Keytruda in a pairing indication.
Merck, based in Kenilworth, NJ and Tokyo-based Isai, said the approval includes the combination for first-line treatment of adults with advanced renal cell carcinoma, the most common type of kidney cancer.
The companies said the combination is now also approved for adults with advanced or recurrent endometrial cancer who have disease progression on prior treatment with platinum-containing therapy in any setting or who are not candidates for palliative surgery or radiation.
In March 2018, Christian and Merck formed a collaboration to jointly develop, manufacture and commercialize Lenvima as monotherapy and in combination with Merck’s blockbuster cancer drug Keytruda.
Write to Colin Kellaher at [email protected]